---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-055500"
form_type: "8-K"
ticker: "BCAX"
cik: "0002023658"
company_name: "Bicara Therapeutics Inc."
filed_at: "2026-08-11T11:36:11+00:00"
generated_at: "2026-08-11T11:40:11.599885+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bicara names Ryan Cohlhepp CEO effective Jan 2027; Q2 net loss widens to $55.4M

## Summary
- Net loss $55.4M in Q2 2026 vs $27.4M in Q2 2025; R&D expense $45.8M (up from $24.8M).
- Cash, equivalents, marketable securities $497.3M at June 30, 2026; funded into 1H 2029.
- Ryan Cohlhepp (President/COO) to become CEO Jan 1, 2027; Claire Mazumdar moves to Vice Chair.
- Tanya Green promoted to COO, Jenn Larson appointed CFO effective Aug 12, 2026; other C-suite changes.
- FORTIFI-HN01 pivotal trial substantially enrolled by year-end; interim topline mid-2027.

## SEC filing metadata
- accession: 0001628280-26-055500
- form_type: 8-K
- ticker: BCAX
- cik: 0002023658
- company_name: Bicara Therapeutics Inc.
- filed_at: 2026-08-11T11:36:11+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023658/000162828026055500/0001628280-26-055500-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023658/000162828026055500/bcax-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-055500
- JSON: https://secwatch.observer/filing/0001628280-26-055500.json
- Plain text: https://secwatch.observer/filing/0001628280-26-055500.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.